Nuclidium bets on copper as radiopharma moves beyond alpha-versus-beta debate

▤ Summary

Nuclidium is positioning copper-based radiopharmaceuticals as the market moves past a simple alpha-versus-beta framing. The company’s CEO says the key question now is which tumor types and therapy lines to target. The article also notes that radiopharma has attracted major investment, partnerships, and acquisitions over the past two years. This makes the piece an industry outlook story rather than a company event announcement.

▦ Linked Companies